Latest Breaking News On - Karen preble - Page 4 : vimarsana.com

Intercept Pharma (ICPT) Resubmits NDA to FDA for Obeticholic Acid in Patients with Liver Fibrosis cause by NASH

Intercept Pharma (ICPT) Resubmits NDA to FDA for Obeticholic Acid in Patients with Liver Fibrosis cause by NASH
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nareg sagherianKaren prebleJerry dursoCompany on twitterGlobal corporate communicationsIntercept pharmaceuticals incDrug administrationNew drug applicationChief executive officerRandomized global phaseObeticholic acid treatmentLiver fibrosisExecutive directorGlobal investorGlobal corporateIntercept pharmaceuticals

Intercept Resubmits New Drug Application to U S FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH

NDA supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study NDA includes detailed safety analysis of 2,477 patients with. | December 23, 2022

Nareg sagherianKaren prebleJerry dursoCompany on twitterGlobal corporate communicationsIntercept pharmaceuticals incDrug administrationGlobenewswire incNew drug applicationChief executive officerRandomized global phaseObeticholic acid treatmentLiver fibrosisExecutive directorGlobal investorGlobal corporate

New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease

New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDavidej jonesNareg sagherianM michelle berreyKaren prebleFiona oakleyCompany on twitterResearch developmentNewcastle universityGlobal corporate communicationsIntercept pharmaceuticals incWarfarinthe international normalized ratioWall streetAmerican journalChief medical officerAcid binding resinsbile

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesNareg sagherianM michelle berreyKaren prebleGlobal corporate communicationsCompany on twitterIntercept pharmaceuticals incResearch developmentLiver meetingIntercept pharmaceuticalsAmerican associationLiver diseasesSevere alcohol associated hepatitisChief medical officerExecutive director

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022 - read this article along with other careers information, tips and advice on BioSpace

Nareg sagherianKaren prebleKrisv kowdleyWashington state universityKomodo healthElsons floyd college of medicineLiver instituteGlobal corporate communicationsIntercept pharmaceuticals incLiver meetingAmerican associationLiver diseasesObeticholic acidExternal controlClinical outcomesPrimary biliary cholangitis